|Bid||7.6500 x 900|
|Ask||7.6900 x 800|
|Day's Range||7.6100 - 7.7000|
|52 Week Range||4.1000 - 14.0000|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.60|
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Northeast ...
HENDERSON, NV / ACCESSWIRE / August 14, 2018 / The global coffee market, which is one of the most valuable commodities globally is valued at about $80 billion per year. Nonetheless, the global cannabis ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 8) AstraZeneca plc (ADR) (NYSE: AZN ) Bio-Rad Laboratories, Inc. ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Elizabeth Bohlen as a new independent member of its Board of Directors. Ms. Bohlen is the chief operating officer of the Archdiocese of Chicago, where she oversees the organization’s administrative functions. She joined the Archdiocese in 2011 after 16 years at McKinsey & Co., where, as a partner, she provided strategic counsel to multinational companies across the retail, consumer and healthcare industries.
Insys Therapeutics Inc. has agreed to pay $150 million to settle a U.S. Department of Justice investigation into the company’s past sales and commercial practices. The pharmaceutical company said Wednesday that it had reached an agreement in principle with the Justice Department. Insys, which set aside $150 million last year in connection with the investigation, said it would pay the settlement over five years.
Insys Therapeutics (INSY) delivered earnings and revenue surprises of -120.00% and -7.67%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Chandler, Arizona-based company said it had a loss of 37 cents per share. Losses, adjusted for stock option expense, were 33 cents per share. The specialty pharmaceutical company posted revenue of ...
PHOENIX, Aug. 08, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results for ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Insys Therapeutics, Inc. (NASDAQ: INSY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 5:00 PM Eastern ...
Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication. Insys announced the tentative deal shortly before a former district sales manager pleaded guilty in a federal court in Connecticut to engaging in a scheme to pay medical practitioners kickbacks to prescribe the company's opioid product Subsys. The plea by Jeffrey Pearlman made him the latest former employee to plead guilty as part of a federal probe that has led to several former executives and doctors being charged, including billionaire Insys founder John Kapoor.
CORAL GABLES, FL / ACCESSWIRE / August 8, 2018 / Healthcare and biotechnology have not faltered during recent weeks. A number of mid and late-stage biotech stocks have begun reporting pivotal research progress that could help bolster more attention in the market. In line with this, the iShares Biotechnology Index (IBB) has risen an impressive 8.9% this year, and the market for small, early-stage biotech stocks is even more active than the industry tracking index suggests.
Pharmaceutical company Insys Therapeutics Inc. said it reached a $150 million settlement with the U.S. Department of Justice to resolve a civil and criminal probe into inappropriate sales of opioid-based painkillers by former employees. The settlement will be paid over five years and could increase by as much as $75 million in contingency-based payments if certain unspecified events occur before the deal is finalized, the Chandler, Arizona-based company said Wednesday in a statement. “This is a very important step for our company to move forward and continue our transformative efforts to foster a compliant and ethical culture,” Saeed Motahari, the company’s chief executive officer, said in the statement.
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has reached an agreement in principle with the Department of Justice (DOJ) to settle the DOJ’s civil and criminal investigation into inappropriate sales and commercial practices by some former company employees. Consistent with previous public statements and disclosures, the terms of this agreement in principle call for INSYS to pay $150 million over five years, with the potential for contingency-based payments associated with certain events that, if they were to occur, management estimates would require additional payments ranging from $0 to $75 million.
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Insys Therapeutics, Inc. breached their fiduciary duties to shareholders.
Insys continues to suck in investors who think the company is ripe for a good study result or positive nod from the U.S. Food & Drug Administration (FDA) -- and that its cheap. The latest rejection came on Friday when the FDA decided not to approve Insys' drug buprenorphine sublingual spray to treat pain as an alternative to opioids.
Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys shares slid nearly 9 percent to $6.62 on Friday, hitting their lowest level in more than two months. Insys' treatment is an under-the-tongue spray formulation of the opioid buprenorphine that was under review to treat moderate-to-severe pain.
Shares of biotech Insys Therapeutics Inc. (insy) slid 7.6% Friday, after the company said the U.S. Food and Drug Administration has declined to approve its new drug application for a spray that treats pain and could offer an alternative to opioids. The company said it has received a Complete Response Letter from the regulator regarding a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain. "Given the attributes of our proprietary buprenorphine formulation for sublingual delivery, we continue to believe that this drug-device combination could bring value to the management of pain and will assess the next steps in the context of the company's overall mission," said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics.
INSYS Therapeutics, Inc. (INSY) announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application (NDA) for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain. Consistent with the outcome of an FDA Advisory Committee meeting in May, the CRL indicates that, although the clinical development program demonstrated all three proposed doses of the product candidate were statistically significantly different than placebo in providing pain relief, some of the data suggested potential safety concerns. “Given the attributes of our proprietary buprenorphine formulation for sublingual delivery, we continue to believe that this drug-device combination could bring value to the management of pain and will assess the next steps in the context of the company’s overall mission,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics.
PHOENIX, July 25, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release ...
U.S. prosecutors on Tuesday said they will narrow a case against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe a potent opioid after a federal judge questioned the scope of the indictment charging them. Federal prosecutors in Boston, in a court filing, said they plan to seek a revised indictment against billionaire Insys (INSY.O) founder John Kapoor and six former executives and managers that will "streamline" the case by including fewer charges. Prosecutors did not say what charges the new indictment would include.